---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-001757"
form_type: "8-K"
ticker: "BYSI"
cik: "0001677940"
company_name: "BeyondSpring Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T03:57:11.143194+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BeyondSpring FY2024 net loss $8.9M; Plinabulin Phase 3 shows OS benefit in NSCLC

## Summary
- Net loss from continuing ops $8.9M vs $14.0M in 2023; R&D expenses fell to $2.6M from $7.3M.
- Plinabulin Phase 3 data published in Lancet Respiratory Medicine: statistically significant overall survival benefit in 2L/3L NSCLC EGFR wild-type vs docetaxel.
- Agreement to sell portion of SEED shares for ~$35.4M gross proceeds; first close of $7.35M in Feb 2025.
- SEED entered Eisai research collaboration with potential payments up to $1.5B; completed $24M Series A-3 first close led by Eisai.
- SEED's RBM39 degrader ST-01156 granted Rare Pediatric Disease and Orphan Drug Designations by FDA.

## SEC filing metadata
- accession: 0001171843-25-001757
- form_type: 8-K
- ticker: BYSI
- cik: 0001677940
- company_name: BeyondSpring Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1677940/000117184325001757/0001171843-25-001757-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1677940/000117184325001757/f8k_032725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-001757
- JSON: https://secwatch.observer/filing/0001171843-25-001757.json
- Plain text: https://secwatch.observer/filing/0001171843-25-001757.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.